Home / Publication / Model-informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

刊物

Model-informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

Author(s): Neeraj Gupta, Michael J. Hanley, Paul M. Diderichsen, Huyuan Yang, Alice Ke, Zhaoyang Teng, Richard Labotka, Deborah Berg, Chirag Patel, Guohui Liu, Helgi van de Velde, Karthik Venkatakrishnan

Year: 2018 年 2 月 15 日

Using cost-effectiveness models for smarter drug development and healthcare decisions

博客

Delivering DSUR Excellence for Multinational Biopharma

案例研究

Model-Based Meta-Analysis (MBMA) for Relative Treatment Effects and Absolute Outcomes: A Focus on Concepts and Applications

网络研讨会

Standardizing Real World Data in Rare Disease: ATHN’s Journey

案例研究

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

Model-informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

Model-informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

Using cost-effectiveness models for smarter drug development and healthcare decisions

Delivering DSUR Excellence for Multinational Biopharma

Model-Based Meta-Analysis (MBMA) for Relative Treatment Effects and Absolute Outcomes: A Focus on Concepts and Applications

Standardizing Real World Data in Rare Disease: ATHN’s Journey

订阅时事通讯

快捷链接

解决方案

联系我们